Aligos Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Aligos Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2019 to 2023.
  • Aligos Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was -$19K, a 1800% decline year-over-year.
  • Aligos Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $88.3M.
  • Aligos Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $164K.
  • Aligos Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $78.7M.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $88.3M* +$88.2M Jan 1, 2023 Dec 31, 2023 10-K 2024-03-12
2022 $164K -$78.5M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-12
2021 $78.7M* -$114M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 $192M* +$107M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 $85.5M* Jan 1, 2019 Dec 31, 2019 10-K 2021-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.